全文获取类型
收费全文 | 994篇 |
免费 | 42篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 31篇 |
妇产科学 | 20篇 |
基础医学 | 94篇 |
口腔科学 | 19篇 |
临床医学 | 122篇 |
内科学 | 230篇 |
皮肤病学 | 41篇 |
神经病学 | 66篇 |
特种医学 | 121篇 |
外科学 | 50篇 |
综合类 | 72篇 |
预防医学 | 38篇 |
眼科学 | 20篇 |
药学 | 32篇 |
中国医学 | 1篇 |
肿瘤学 | 101篇 |
出版年
2022年 | 5篇 |
2021年 | 12篇 |
2020年 | 6篇 |
2019年 | 5篇 |
2018年 | 10篇 |
2017年 | 9篇 |
2016年 | 17篇 |
2015年 | 11篇 |
2014年 | 28篇 |
2013年 | 71篇 |
2012年 | 33篇 |
2011年 | 31篇 |
2010年 | 38篇 |
2009年 | 33篇 |
2008年 | 19篇 |
2007年 | 42篇 |
2006年 | 20篇 |
2005年 | 19篇 |
2004年 | 16篇 |
2003年 | 16篇 |
2002年 | 14篇 |
2001年 | 15篇 |
2000年 | 19篇 |
1999年 | 17篇 |
1998年 | 52篇 |
1997年 | 50篇 |
1996年 | 38篇 |
1995年 | 27篇 |
1994年 | 31篇 |
1993年 | 35篇 |
1992年 | 7篇 |
1991年 | 11篇 |
1990年 | 16篇 |
1989年 | 40篇 |
1988年 | 21篇 |
1987年 | 23篇 |
1986年 | 19篇 |
1985年 | 8篇 |
1984年 | 9篇 |
1983年 | 7篇 |
1982年 | 10篇 |
1981年 | 10篇 |
1980年 | 10篇 |
1977年 | 5篇 |
1976年 | 8篇 |
1975年 | 6篇 |
1963年 | 6篇 |
1962年 | 5篇 |
1960年 | 5篇 |
1941年 | 11篇 |
排序方式: 共有1060条查询结果,搜索用时 0 毫秒
41.
42.
43.
44.
Cocaine use in pregnancy in Amsterdam 总被引:1,自引:0,他引:1
BJ Smit K Boer AM van Huis ISE Lie-A-Ling SC Schmidt 《Acta paediatrica (Oslo, Norway : 1992)》1994,83(S404):32-35
To study the effects of cocaine use in pregnancy in Amsterdam, clinical data on cocaine-using pregnant women ( n = 21) and their offspring ( n = 23) were obtained retrospectively (1987–1994) at the Academic Medical Center, Amsterdam. Infants exposed to cocaine had a median gestational age of 39 weeks and a median birth weight of 3090 g. There were six preterm infants, two small-for-gestational-age infants and five infants with a small head circumference. Three infants had a congenital malformation. One infant (Potter's syndrome) died shortly before birth. One infant had congenital syphilis, four had intracerebral abnormalities on ultrasound and four had abnormal neurologic symptoms in the neonatal period. One infant died after 21 days of life. At follow-up four infants showed abnormal development. In 12 of the 23 infants (52%), one or more possible effects of cocaine were found. 相似文献
45.
46.
47.
48.
49.
Rosenstein BS Lymberis SC Formenti SC 《International journal of radiation oncology, biology, physics》2004,60(5):39-1404
PURPOSE: To analyze the dose/fractionation schedules currently used in ongoing clinical trials of partial breast irradiation (PBI) by comparing their biologically effective dose (BED) values to those of three standard whole breast protocols commonly used after segmental mastectomy in the treatment of breast cancer. METHODS AND MATERIALS: The BED equation derived from the linear-quadratic model for radiation-induced cell killing was used to calculate the BEDs for three commonly used whole breast radiotherapy regimens, in addition to a variety of external beam radiotherapy, as well as high-dose-rate and low-dose-rate brachytherapy, PBI protocols. RESULTS: The BED values of most PBI protocols resulted in tumor control BEDs roughly equivalent to a 50-Gy standard treatment, but consistently lower than the BEDs for regimens in which the tumor bed receives a total dose of either 60 Gy or 66 Gy. The BED values calculated for the acute radiation responses of erythema and desquamation were nearly all lower for the PBI schedules, and the late-response BEDs for most PBI regimens were in a similar range to the BEDs for the standard treatments. CONCLUSION: Biologically effective dose modeling raises the concern that inadequate doses might be delivered by PBI to ensure optimal in-field tumor control. 相似文献
50.
Prados MD Schold SC JR SC Fine HA Jaeckle K Hochberg F Mechtler L Fetell MR Phuphanich S Feun L Janus TJ Ford K Graney W 《Neuro-oncology》2003,5(2):96-103
RMP-7, a bradykinin analog, temporarily increases the permeability of the blood-brain tumor barrier to chemotherapy drugs like carboplatin. We conducted a randomized, controlled trial of carboplatin and RMP-7 versus carboplatin and placebo in patients with recurrent malignant glioma. The primary outcome measure was time to tumor progression (TTP). Adults with recurrent glioblastoma multiforme or anaplastic glioma were randomized in a 1:1 ratio to receive carboplatin and either RMP-7 or placebo. Radiation therapy had failed in all patients, and they may have received prior chemotherapy. Carboplatin (dosed to achieve an area under the curve of 5 mg/ml x time for patients who had received prior chemotherapy, or 7 mg/ml x time for those who had not) was given intravenously every 4 weeks, followed by intravenous infusion of either RMP-7 or placebo (300 ng/kg). TTP, tumor response, neuropsychological assessments, functional independence, and quality of life assessments were analyzed every 4 weeks. There were 122 patients enrolled, 62 in the RMP-7 and carboplatin group and 60 in the placebo and carboplatin group. Median TTP was 9.7 weeks (95% CI, 8.3-12.6 weeks) for the RMP-7 and carboplatin group and 8.0 weeks (95% CI, 7.4-12.6 weeks) for the placebo and carboplatin group. Median survival times were 26.9 weeks (95% CI, 21.3-37.6 weeks) for the RMP-7 group and 19.9 weeks (95% CI, 15.0-31.3 weeks) for the placebo group. No differences were noted for time to worsening of neuropsychological assessments, functional independence, or quality of life assessments. The use of RMP-7 had no effect on the pharmacokinetics or toxicity of carboplatin. At the dose and schedule used in this trial, RMP-7 did not improve the efficacy of carboplatin. Recent preclinical pharmacokinetic modeling of RMP-7 suggests that higher doses of RMP-7 may be required to increase carboplatin delivery to tumor. 相似文献